US 11,447,545 B2Granted

Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer

AssigneeInnate Pharma

InventorsStéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann

Life of this patent

Estimating the term…

Abstract

This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

Claims14

Dependent claims

A pharmaceutical composition comprising an antibody that neutralizes the inhibitory activity of NKG2A, and an antibody that neutralizes the inhibitory activity of Siglec-9, wherein the antibody that neutralizes the inhibitory activity of Siglec-9 is selected from the group consisting of:

(a) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
15 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
16;
(b) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
17 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
18;
(c) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
19 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
20;
(d) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
21 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
22;
(e) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
23 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
24;
(f) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
25 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
26;
(g) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
3 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
4;
(h) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
5 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
6;
(i) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
7 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
8;
(j) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
9 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
10;
(k) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
11 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
12;
and
(l) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
13 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
14.

34 more elements

A kit comprising:

(a) a dose of an antibody, that neutralizes the inhibitory activity of NKG2A, and (b) a dose of an antibody, that neutralizes the inhibitory activity of Siglec-9, wherein the antibody that neutralizes the inhibitory activity of Siglec-9 is selected from the group consisting of:
(a) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
15 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
16;
(b) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
17 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
18;
(c) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
19 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
20;
(d) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
21 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
22;
(e) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
23 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
24;
(f) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
25 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
26;
(g) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
3 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
4;
(h) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
5 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
6;
(i) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
7 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
8;
(j) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
9 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
10;
(k) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
11 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
12;
and
(l) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
13 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
14.

35 more elements

An in vitro method for modulating the activity of NKG2A+ Siglec+ lymphocytes, optionally NK cells, optionally CD8+ T cells, comprising bringing lymphocytes expressing at their surface NKG2A and Siglec-9 into contact with an antibody that neutralizes the inhibitory activity of NKG2A and an antibody that neutralizes the inhibitory activity of Siglec-9, wherein the antibody that neutralizes the inhibitory activity of Siglec-9 is selected from the group consisting of:

(a) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
15 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
16;
(b) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
17 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
18;
(c) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
19 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
20;
(d) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
21 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
22;
(e) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
23 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
24;
(f) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
25 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
26;
(g) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
3 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
4;
(h) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
5 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
6;
(i) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
7 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
8;
(j) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
9 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
10;
(k) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
11 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
12;
and
(l) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
13 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
14.

34 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/629,585Filed 9 Jul 2018 · us provisional application
Priority: 10 Jul 2017
Published: US 2020/0369764 A126 Nov 2020
Granted: 20 Sep 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 40/15
Characterised by the cell type used: natural-killer [NK] cells; Natural-killer T [NKT] cells
A61K 40/42
Vertebrate antigens: cancer antigens
A61P 35/00
Antineoplastic agents

Family

Application62/530,454Us provisional application · filed 10 Jul 2017
US 2020/0369764 A1Pre-grant publication · published 26 Nov 2020
US 11,447,545 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

(a) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
15 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
16;
(b) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
17 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
18;
(c) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
19 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
20;
(d) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
21 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
22;
(e) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
23 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
24;
(f) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
25 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
26;
(g) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
3 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
4;
(h) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
5 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
6;
(i) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
7 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
8;
(j) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
9 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
10;
(k) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
11 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
12;
and
(l) a monoclonal antibody comprising (i) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
13 and (ii) a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
14.

34 more elements

Facts

Application

16/629,585Filed 9 Jul 2018 · us provisional application

Priority

10 Jul 2017

Published

US 2020/0369764 A126 Nov 2020

Granted

20 Sep 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 40/15
Characterised by the cell type used: natural-killer [NK] cells; Natural-killer T [NKT] cells
A61K 40/42
Vertebrate antigens: cancer antigens
A61P 35/00
Antineoplastic agents